IDUA Gene

IDUA Gene

Introduction

IDUA (Iduronidase), also known as alpha-L-iduronidase, is a lysosomal hydrolase that catalyzes the hydrolysis of alpha-L-iduronic acid residues from the non-reducing ends of glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate.[@muir2022] This enzyme is essential for the complete lysosomal degradation of GAGs, and its deficiency causes mucopolysaccharidosis type I (MPS I), a severe lysosomal storage disorder characterized by progressive multisystem disease including neurodegeneration.[@lysosomal2024] The IDUA gene encodes a protein of 653 amino acids that is targeted to the lysosome via mannose-6-phosphate modification, and proper enzyme trafficking is essential for its function[@beck2023] [1][2][3][4].

IDUA Gene

Introduction

IDUA (Iduronidase), also known as alpha-L-iduronidase, is a lysosomal hydrolase that catalyzes the hydrolysis of alpha-L-iduronic acid residues from the non-reducing ends of glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate.[@muir2022] This enzyme is essential for the complete lysosomal degradation of GAGs, and its deficiency causes mucopolysaccharidosis type I (MPS I), a severe lysosomal storage disorder characterized by progressive multisystem disease including neurodegeneration.[@lysosomal2024] The IDUA gene encodes a protein of 653 amino acids that is targeted to the lysosome via mannose-6-phosphate modification, and proper enzyme trafficking is essential for its function[@beck2023] [1][2][3][4].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IDUA — Alpha-L-Iduronidase</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>IDUA</td></tr>
<tr><td><strong>Full Name</strong></td><td>Alpha-L-iduronidase</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>4p16.3</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/3419" target="_blank">3419</a></td></tr>
<tr><td><strong>OMIM</strong></td><td><a href="https://www.omim.org/entry/609014" target="_blank">609014</a></td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000127418</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P35475" target="_blank">P35475</a></td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Mucopolysaccharidosis Type I](/diseases/mucopolysaccharidosis-type-1) (Hurler Syndrome), [Scheie Syndrome](/diseases/mucopolysaccharidosis-type-1)</td></tr>
</table>
</div>

Protein Structure and Function

Enzyme Architecture

Alpha-L-iduronidase is a 653-amino acid glycoprotein with a molecular weight of approximately 76 kDa. The enzyme undergoes several post-translational modifications:

Catalytic Mechanism

The enzyme catalyzes the hydrolysis of alpha-L-iduronic acid residues from GAGs through:

• Acid-base catalysis: Residues in the active site facilitate hydrolysis
• Substrate specificity: Recognizes the non-reducing end of heparan sulfate and dermatan sulfate
• Processivity: Acts repeatedly along the GAG chain

Glycosylation and Trafficking

Proper trafficking requires:

• N-linked glycosylation in the ER
• Mannose-6-phosphate modification in the Golgi
• Recognition by mannose-6-phosphate receptors
• Delivery to lysosomes

Normal Function

Glycosaminoglycan Degradation

Alpha-L-iduronidase works in concert with other lysosomal sulfatases to degrade GAGs:

Lysosomal Function

The complete degradation pathway:

• Endocytosis of GAGs: Brought into lysosomes via autophagy
• Sequential hydrolysis: Multiple enzymes act in concert
• Export of degradation products: Transported to the cytosol for reuse

Disease Associations

Mucopolysaccharidosis Type I (MPS I)

MPS I, caused by IDUA deficiency, is a spectrum disorder:

Severe Form (Hurler Syndrome)

• Onset: First year of life
• Progression: Rapid neurodegenerative decline
• Phenotype: Coarse facial features, organomegaly, skeletal abnormalities (dysostosis multiplex)
• Neurological: Hydrocephalus, spinal cord compression, developmental regression
• Survival: Without treatment, Usually fatal in first decade

Attenuated Forms (Scheie/Hurler-Scheie)

• Onset: Childhood to adulthood
• Progression: Slower, variable
• Phenotype: Joint stiffness, corneal clouding, carpal tunnel
• Intelligence: Often normal

Intermediate Form (Hurler-Scheie)

• Onset: 2-4 years
• Progression: Intermediate
• Survival: Into adolescence or early adulthood

Neuroimaging Findings

In MPS I, brain imaging reveals [12]:

• White matter abnormalities: Periventricular hyperintensities
• Hydrocephalus: Communicating hydrocephalus common
• Cervical compression: Foramen magnum stenosis
• Carotid artery disease: Vessel wall thickening

Cognitive Outcomes

Neurocognitive decline in MPS I involves [13]:

• Developmental regression
• Impaired processing speed
• Executive dysfunction
• Language regression

Therapeutic Approaches

Enzyme Replacement Therapy (ERT)

Recombinant human alpha-L-iduronidase (laronidase, Aldurazyme):

• Delivery: Weekly intravenous infusions
• Effects: Reduces substrate storage, improves endurance
• Limitations: Does not cross the blood-brain barrier
• CNS effects: Minimal (BBB limits CNS benefit)

Hematopoietic Stem Cell Transplantation (HSCT)

HSCT provides:

• Enzyme source: Donor-derived cells produce enzyme
• Microglial replacement: CNS engrafts with donor microglia
• Stabilization: Can halt neurological progression
• Risks: Graft-versus-host disease, mortality

Gene Therapy

AAV-mediated IDUA delivery has shown promise in animal models [8][9]:

• Vectors: AAV9, AAVrh.10 (CNS targeting)
• Delivery: Intravenous or intrathecal administration
• Efficacy: Reverses storage in models
• Clinical trials: In development

Substrate Reduction Therapy

Approaches to reduce GAG substrate accumulation [10]:

• Small molecule inhibitors: Reduce GAG synthesis
• Combination with ERT: May enhance efficacy
• Limitations: Not clinically approved for MPS I

Newborn Screening

Early detection enables [11]:

• Early treatment initiation
• Pre-symptomatic therapy
• Optimized outcomes
• Family counseling

Expression Pattern

Tissue Distribution

Alpha-L-iduronidase is expressed in most tissues:

• Highest: Liver, spleen, kidney
• Moderate: Brain, lung, heart
• Cellular: Especially in macrophages and microglia

CNS Expression

Within the brain:

• Neurons: Variable expression
• Astrocytes: Baseline expression
• Microglia: High expression (important for therapy)
• Choroid plexus: Contributes to CSF enzyme

Pathophysiology

Storage Material

The storage material in MPS I consists of:

• Heparan sulfate: Primary storage in neurons
• Dermatan sulfate: Storage throughout body
• Partial degradation products: Accumulate as storage

Cellular Pathology

Blood-Brain Barrier

The BBB presents a therapeutic challenge:

• Standard ERT does not cross BBB

• Gene therapy vectors are being engineered for BBB penetration

Animal Models

Knockout Mice

Idua knockout mice display:

• Storage accumulation
• shortened lifespan
• Behavior abnormalities with age

Canine Models

MPS I in dogs shows:

• More severe phenotype
• Good model for therapy studies

Large Animal Models

Swine and non-human primate models are used for translational studies.

Mermaid Diagram: IDUA Function and Therapy

Genotype-Phenotype Correlation

Common Mutations

IDUA mutations show variety:

• Missense mutations: Most common
• Nonsense mutations: Severe phenotype
• Splice site mutations: Variable

Genotype-Phenotype Relationships

Certain mutations correlate with [12]:

• Severe phenotype: Q70X, W402X
• Attenuated: A327T, P533R

References

Biochemical Properties

Enzyme Kinetics

Alpha-L-iduronidase exhibits classic Michaelis-Menten kinetics:

• Substrate affinity: Km in the micromolar range for natural substrates
• Catalytic efficiency: kcat/Km values indicate efficient catalysis
• pH optimum: Optimal activity at pH 4.5-5.0 (lysosomal pH)
• Temperature stability: Stable at physiological temperatures

Structural Features

The enzyme contains several key structural elements:

• Active site: Catalytic residue in the center of the protein
• Substrate binding groove: Accommodates heparan sulfate and dermatan sulfate
• N-linked glycans: Multiple sites for mannose-6-phosphate modification
• Dimerization interface: Forms dimers at lysosomal pH

Post-Translational Modifications

Critical modifications for function:

Research History

Historical Milestones

The understanding of IDUA and MPS I has evolved over decades:

1970s:

• First description of alpha-L-iduronidase deficiency
• Recognition of Hurler and Scheie as same enzyme defect
• Development of first diagnostic methods

• Purification of recombinant enzyme
• Development of animal models
• First attempts at enzyme replacement

• CDNA cloning and sequencing
• Structure-function studies
• Development of laronidase (Aldurazyme)

• FDA approval of enzyme replacement therapy
• Long-term outcome studies
• Development of HSCT protocols

• Gene therapy advances
• Newborn screening implementation
• BBB-penetrant therapy development

• AAV clinical trials initiating
• Gene editing approaches
• Combination therapy trials

Clinical Management

Diagnostic Approach

Initial evaluation for suspected MPS I includes:

Monitoring and Follow-up

Patients require regular monitoring:

| Parameter | Frequency |
|-----------|-----------|
| Neurological exam | Every 6 months |
| Neuroimaging | Annually or as indicated |
| Cognitive testing | Every 6-12 months |
| Cardiac evaluation | Annually |
| Ophthalmologic exam | Annually |
| Auditory testing | Annually |
| Pulmonary function | Every 6-12 months |
| Orthopedic evaluation | As indicated |

Supportive Care

Comprehensive supportive care includes:

Emerging Therapies

The field is advancing rapidly:

Animal Model Studies

Mouse Models

Idua knockout mice recapitulate human disease:

• Accumulation of GAGs in tissues
• CNS storage and inflammation
• Facial dysmorphia
• Reduced lifespan

Canine Models

MPS I in dogs shows:

• More severe phenotype than mice
• CNS involvement similar to humans
• Good model for therapy studies
• Predicts human outcomes

Translational Studies

Key findings from animal models:

Pharmacogenetics

Genotype-Phenotype Relationships

Specific mutations correlate with phenotypes:

| Mutation | Severity | Notes |
|---------|----------|-------|
| Q70X | Severe | Nonsense, no functional protein |
| W402X | Severe | Common, founder mutations |
| A327T | Attenuated | Reduced activity |
| P533R | Attenuated | Residual activity |
| R89Q | Variable | Modified by other factors |

Ethnic Distribution

Founder mutations vary by population:

• W402X: European populations
• Q70X: Various
• A75P: Finnish population

Public Health Impact

Epidemiology

MPS I epidemiology:

• Incidence: 1 in 100,000 live births
• Carrier frequency: ~1 in 250 (carrier)
• Geographic variation: Higher in some regions

Newborn Screening

Many regions have implemented NBS:

Health Economics

Disease burden considerations:

• High treatment costs: ERT > $500K/year
• HSCT costs: $500K-1M per procedure
• Long-term care: Significant ongoing costs
• Quality of life: Important outcome measure

See Also

• [Alpha-L-iduronidase Protein](/proteins/alpha-l-iduronidase)
• [Mucopolysaccharidosis Type I](/diseases/mucopolysaccharidosis-type-1)
• [Hurler Syndrome](/diseases/hurler-syndrome)
• [Scheie Syndrome](/diseases/scheie-syndrome)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Glycosaminoglycans](/proteins/glycosaminoglycans)
• [Enzyme Replacement Therapy](/mechanisms/enzyme-replacement-therapy)
• [Gene Therapy for Neurodegeneration](/mechanisms/gene-therapy)
• [Hematopoietic Stem Cell Transplantation](/mechanisms/hsct)

Pathway Diagram

The following diagram shows the key molecular relationships involving IDUA Gene discovered through SciDEX knowledge graph analysis: